Literature DB >> 8753684

Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours.

S Ho1, W Y Lau, T W Leung, M Chan, Y K Ngar, P J Johnson, A K Li.   

Abstract

A uniform distribution of yttrium-90 (90Y) microspheres throughout the entire liver has always been assumed for dose calculation in treating hepatic tumours. A simple mathematical model was formulated which allows estimation of the activities of a therapeutic dose of 90Y microspheres partitioned between the lungs, the tumour and the normal liver, and hence the radiation doses to them. The doses to the tumour and normal liver were verified by intra-operative direct beta-probing. The percentage of activity shunted to the lung and the tumour-to-normal tissue ratio (T/N) were obtained from gamma scintigraphy using technetium-99m-labelled macroaggregated albumin (MAA) which simulates the 90Y microspheres used in subsequent treatment. The intrahepatic activity was partitioned between the tumour and the normal liver based on the T/N and their masses determined from computerized tomography slices. The corresponding radiation doses were computed using the MIRD formula. The estimated radiation doses were correlated with the doses directly measured using a calibrated beta-probe at laparotomy by linear regression. The radiation doses to the tumour and the normal liver, estimated using the partition model, were close to that measured directly with coefficients of correlation for linear regression: 0.862 for the tumours and 0.804 for the normal liver compartment (P<0.001). The partition model permits a distinction between the radiation doses received by the tumour and the normal liver to be made and the doses thus estimated are close to the actual doses received. The optimal doses to the tumour and normal liver and hence the required quantity of 90Y microspheres to be administered can be easily predetermined.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8753684     DOI: 10.1007/bf01084369

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  25 in total

1.  Dose distribution following selective internal radiation therapy.

Authors:  R A Fox; P F Klemp; G Egan; L L Mina; M A Burton; B N Gray
Journal:  Int J Radiat Oncol Biol Phys       Date:  1991-07       Impact factor: 7.038

2.  Three-dimensional tumor dosimetry for hepatic yttrium-90-microsphere therapy.

Authors:  P L Roberson; R K Ten Haken; D L McShan; P E McKeever; W D Ensminger
Journal:  J Nucl Med       Date:  1992-05       Impact factor: 10.057

3.  Therapeutic aspects of radioisotopes in hepatobiliary malignancy.

Authors:  W Y Lau; A K Li
Journal:  Br J Surg       Date:  1992-07       Impact factor: 6.939

4.  Intraoperative dosimetry of 90Y in liver tissue.

Authors:  M A Burton; B N Gray; C Jones; A Coletti
Journal:  Int J Rad Appl Instrum B       Date:  1989

5.  Tolerance of the liver to the effects of Yttrium-90 radiation.

Authors:  B N Gray; M A Burton; D Kelleher; P Klemp; L Matz
Journal:  Int J Radiat Oncol Biol Phys       Date:  1990-03       Impact factor: 7.038

6.  Treatment of inoperable cancer of the liver by intra-arterial radioactive isotopes and chemotherapy.

Authors:  I M Ariel; G T Pack
Journal:  Cancer       Date:  1967-05       Impact factor: 6.860

7.  A phase I dose escalation trial of yttrium-90 microspheres in the treatment of primary hepatocellular carcinoma.

Authors:  F A Shepherd; L E Rotstein; S Houle; T C Yip; K Paul; K W Sniderman
Journal:  Cancer       Date:  1992-11-01       Impact factor: 6.860

8.  Quantitative bremsstrahlung imaging of yttrium-90 using a Wiener filter.

Authors:  S Shen; G L DeNardo; S J DeNardo
Journal:  Med Phys       Date:  1994-09       Impact factor: 4.071

9.  Diagnostic pharmaco-scintigraphy with hepatic intra-arterial technetium-99m macroaggregated albumin in the determination of tumour to non-tumour uptake ratio in hepatocellular carcinoma.

Authors:  W Y Lau; T W Leung; S Ho; M Chan; N W Leung; J Lin; C Metreweli; A K Li
Journal:  Br J Radiol       Date:  1994-02       Impact factor: 3.039

10.  Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study.

Authors:  W Y Lau; W T Leung; S Ho; N W Leung; M Chan; J Lin; C Metreweli; P Johnson; A K Li
Journal:  Br J Cancer       Date:  1994-11       Impact factor: 7.640

View more
  65 in total

Review 1.  Radioembolization for primary and metastatic liver cancer.

Authors:  Khairuddin Memon; Robert J Lewandowski; Laura Kulik; Ahsun Riaz; Mary F Mulcahy; Riad Salem
Journal:  Semin Radiat Oncol       Date:  2011-10       Impact factor: 5.934

2.  Grey Turner Memorial Lecture. Changing role of liver surgeons.

Authors:  A K Li
Journal:  World J Surg       Date:  1999-01       Impact factor: 3.352

Review 3.  Yttrium-90 Radioembolization Dosimetry: What Trainees Need to Know.

Authors:  Alexander Villalobos; Mohamed M Soliman; Bill S Majdalany; David M Schuster; James Galt; Zachary L Bercu; Nima Kokabi
Journal:  Semin Intervent Radiol       Date:  2020-12-11       Impact factor: 1.513

4.  Radioembolization with 90Y glass microspheres for hepatocellular carcinoma: significance of pretreatment 11C-acetate and 18F-FDG PET/CT and posttreatment 90Y PET/CT in individualized dose prescription.

Authors:  Chi Lai Ho; Sirong Chen; Shing Kee Cheung; Yim Lung Leung; Kam Chau Cheng; Ka Nin Wong; Yuet Hung Wong; Thomas Wai Tong Leung
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-06-11       Impact factor: 9.236

Review 5.  SIR-Spheres yttrium-90 radioembolization for the treatment of unresectable liver cancers.

Authors:  Rita Golfieri
Journal:  Hepat Oncol       Date:  2014-09-09

6.  (⁹⁹m)Tc-MAA overestimates the absorbed dose to the lungs in radioembolization: a quantitative evaluation in patients treated with ¹⁶⁶Ho-microspheres.

Authors:  Mattijs Elschot; Johannes F W Nijsen; Marnix G E H Lam; Maarten L J Smits; Jip F Prince; Max A Viergever; Maurice A A J van den Bosch; Bernard A Zonnenberg; Hugo W A M de Jong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-05-13       Impact factor: 9.236

7.  Personalized Dosimetry for Liver Cancer Y-90 Radioembolization Using Computational Fluid Dynamics and Monte Carlo Simulation.

Authors:  Emilie Roncali; Amirtahà Taebi; Cameron Foster; Catherine Tram Vu
Journal:  Ann Biomed Eng       Date:  2020-01-31       Impact factor: 3.934

8.  Selective Internal Radiation Therapy With Yttrium-90 Glass Microspheres: Biases and Uncertainties in Absorbed Dose Calculations Between Clinical Dosimetry Models.

Authors:  Justin K Mikell; Armeen Mahvash; Wendy Siman; Veera Baladandayuthapani; Firas Mourtada; S Cheenu Kappadath
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-07-27       Impact factor: 7.038

9.  Salvage surgery following downstaging of unresectable hepatocellular carcinoma.

Authors:  Wan-yee Lau; Stephen K W Ho; Simon C H Yu; Eric C H Lai; Choong-tsek Liew; Thomas W T Leung
Journal:  Ann Surg       Date:  2004-08       Impact factor: 12.969

10.  Holmium-166 poly(L-lactic acid) microsphere radioembolisation of the liver: technical aspects studied in a large animal model.

Authors:  M A D Vente; T C de Wit; M A A J van den Bosch; W Bult; P R Seevinck; B A Zonnenberg; H W A M de Jong; G C Krijger; C J G Bakker; A D van het Schip; J F W Nijsen
Journal:  Eur Radiol       Date:  2009-09-30       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.